Wilprafen solutab, as a macrolide antibiotic, is commonly used to help manage various bacterial infections. This medicine is generally applied in clinical settings that involve acute or unstable symptom patterns affecting the lungs, throat, ear, and sinuses, or for infections of the skin and soft tissues. It is also considered relevant for conditions arising from specific atypical urogenital pathogens, such as Chlamydia and Mycoplasma. The primary therapeutic benefit is to support the body's recovery by managing the presence of the infectious organisms, which generally helps ease the overall symptom burden.

The medication is commonly used to help with symptoms arising from conditions like bronchitis, community-acquired pneumonia, tonsillitis, otitis media, urethritis, and pyoderma.

“This macrolide provides therapeutic support and assists the patient during difficult episodes by easing distress.”

A common clinical scenario is its use as a systemic therapeutic alternative for individuals who require antibiotic treatment but may have documented hypersensitivity to penicillin-class drugs, contributing to symptomatic support.

---

Quick Fact: Relief for Acute Inflammation This medicine is applied to address symptoms related to inflammatory or irritative states where functional stability becomes affected, helping patients cope more steadily with symptom fluctuations.

---

Regulatory References

1. NIH StatPearls overview of Macrolide uses

The eligibility profile for Wilprafen solutab is defined by regulatory criteria that strictly delineate who may use the medicine and who is absolutely excluded. This information is derived from official regulatory labeling, focusing on documented contraindications and population-specific restrictions.

Contraindicated Populations

Use of Wilprafen solutab is contraindicated and strictly prohibited for individuals who have a known hypersensitivity or allergic reaction to Josamycin, its active ingredient, or to any other medicinal product belonging to the macrolide antibiotic class. The medicine is also contraindicated in patients diagnosed with severe hepatic insufficiency (severe liver disease), due to the body’s limited ability to process the active substance.

Conditional and Restricted Use

The medicine is documented for use across broad age groups, including pediatric, adult, and older adult populations, with the dispersible Solutab formulation designed for ease of administration in children. However, regulatory documents advise use with caution for patients with pre-existing, non-severe liver impairment. For women who are pregnant or breastfeeding, the official regulatory status is classified as safety not fully established, which imposes a conditional use restriction.

Interactions with other medicines and products

The interaction profile of Wilprafen solutab (Josamycin) is primarily defined by its documented potential to interfere with the metabolism of numerous co-administered medicines.

Documented Interaction Mechanism and Effects

Category	Official Regulatory Documentation
Mechanistic Basis	Josamycin is classified as a potent inhibitor of the drug-metabolizing enzyme CYP3A4 in the liver.
Effect	This mechanism decreases the clearance of various drugs, resulting in increased plasma concentrations and elevated exposure (AUC/Cmax) for the co-administered substance.

Interaction-Related Restrictions and Constraints

Co-administration of Wilprafen solutab is subject to specific regulatory restrictions due to the risk of increased exposure:

• Formal Contraindications: Use is contra-indicated with Ivabradine and Eletriptan. Combining these substances is prohibited due to the significant and documented increase in their plasma exposure.
• Exposure-Modifying Interactions: Josamycin may decrease the metabolism of several drug categories, including Anticoagulants (such as Warfarin), HMG-CoA Reductase Inhibitors (Statins like Atorvastatin), Immunosuppressants (Cyclosporine), and Anti-epileptics (Carbamazepine). This interaction results in increased serum concentrations of the co-administered drug.
• Pharmacodynamic Interactions: The medicine may increase the QTc-prolonging activities of Disopyramide and the neuromuscular blocking activities of agents such as Cisatracurium.
• Population-Specific Note: The clinical significance of exposure-modifying interactions may be heightened in patients with compromised hepatic (liver) function.

How Wilprafen Solutab Works: Mechanism of Action

Wilprafen Solutab contains Josamycin, a molecule that exerts its effect by targeting the core machinery of susceptible bacteria—the 50S ribosomal subunit. The drug acts as an inhibitor by binding non-covalently within the nascent peptide exit tunnel (NPET). This interaction physically blocks the continuous formation and elongation of polypeptide chains, thereby disrupting the fundamental biological pathway of protein synthesis.

The interruption of protein production impacts the pathogen's cellular viability and growth pathway. This mechanistic cascade prevents the pathogen from growing, dividing, and maintaining its internal structure. The consequence is the arrest of bacterial proliferation (bacteriostasis), which results in the reduction of the active bacterial population within the host.

The activity of this mechanism can be physiologically constrained by bacterial defenses. Examples include the expression of efflux pumps that actively expel Josamycin from the cell or chemical modification of the ribosomal binding site, both of which limit the drug’s inhibitory action.

The administration of Wilprafen solutab, which contains the active ingredient Josamycin, is strictly governed by the product's formulation as a dispersible tablet (Solutab), defining its approved use protocol. The official and only route of administration is oral, requiring mandatory preparation prior to intake. The tablet is not to be swallowed whole; instead, it must be dissolved completely in a minimum of 50 mL of water and stirred thoroughly to create a uniform oral suspension. This prepared mixture should then be consumed immediately, adhering to the instruction that the solid form is never ingested directly.

For adults, the standard daily dose of Josamycin typically falls within the range of 800 mg to 1,200 mg. This total amount is officially required to be divided into three or four equal administrations distributed over the course of the day, a schedule designed to maintain consistent systemic levels. The dose is generally permitted to be taken either with or without food.

Specific instructions apply to pediatric use, where the required dose is calculated based on body weight at 30 mg/kg per day, also administered in divided daily doses. The duration of the course is a short-term commitment, often cited as approximately ten days for various acute infections. In the event a dose is missed, official guidance states that the user should skip the missed dose and resume the normal schedule, without taking a double quantity to compensate.

Evidence for Infections of the Lungs and Airways (Respiratory Tract)

Research has explored Josamycin in the context of conditions characterized by acute or disruptive episodes, such as Community-Acquired Pneumonia (CAP). Controlled clinical trials and prospective evaluations were utilized, examining outcomes related to systemic or functional imbalance, including the time until fever resolution and the rate of pathogen clearance (microbiological outcome). For acute bronchitis, research was observed in large patient groups through observational settings. These studies monitored outcomes related to episodic or acute changes in symptoms. The body of evidence for these respiratory conditions is categorized as moderate, but many available studies reflect earlier periods of clinical research.

---

Evidence for Atypical Urogenital Infections

Josamycin was studied for its profile against specific atypical pathogens, including Chlamydia trachomatis and Mycoplasma hominis. Small comparative clinical trials were conducted, primarily examining the microbiological outcome—the non-detection of the pathogen following the study period. For Chronic Prostatitis, studies examined changes measured using specific functional scales. The body of evidence for these targeted areas is categorized as moderate to high; however, evidence quality varies across studies. Sample sizes were modest in the comparative trials, and some findings are uncertain due to the use of Josamycin alongside other agents.

---

Long-Term Studies and Follow-up Durations

The research has observed patient responses mainly over defined, short-term time intervals (e.g., 7 to 14 days). Follow-up was monitored out to an intermediate-term period of up to six weeks to check for signs of recurrence or relapse. Crucially, long-term outcomes are not fully established; the research base has limited information for long-term outcomes across the board. The overall research highlights what is known—and what is still uncertain.

Key Studies & References

1. Efficacy and Safety of Josamycin in the Treatment of Mild-to-Moderate Community-Acquired Pneumonia: Results of Multicenter Clinical Study
2. [Rokitamycin in the Treatment of Female Genital Chlamydia and Mycoplasma Infections. Comparative Study vs Josamycin]
3. Applications of Josamycin in the Treatment of Urethrogenic Prostatitis
4. Macrolides for the treatment of chronic bacterial prostatitis
5. Urogenital chlamydia infection in women: patient management tactics according to present-day foreign and Russian recommendations

Common questions about Wilprafen solutab (FAQ)

Q: Does Wilprafen solutab belong to the penicillin group of antibiotics?

A: No, according to official product information, Wilprafen solutab is classified as a macrolide antibiotic. Macrolides are a distinct class of antibacterial medicines that work differently from penicillin to treat bacterial infections.

Q: Can Wilprafen solutab be taken without food or with food?

A: Regulatory documents indicate that Wilprafen solutab tablets should generally be taken between meals. This approach is recommended to ensure optimal absorption and efficacy, as indicated in the product information.

Q: How long is the typical course of treatment with Wilprafen solutab?

A: The typical duration of treatment, according to the official product information, is usually between 7 and 10 days. Official guidelines state that the specific duration of treatment is determined by the healthcare provider based on the type and severity of the infection.

Q: What should I do if I miss a dose of Wilprafen solutab?

A: If a dose is missed, official guidance suggests taking it as soon as the lapse is noticed, unless it is nearly time for the next scheduled dose. If so, the missed dose should be skipped, and resume the regular schedule, avoiding taking two doses simultaneously to make up for the missed dose.

Q: What is the recommended maximum daily dose for children?

A: The regulatory documents state that the dosage for children is calculated based on their body weight, typically in milligrams per kilogram of body weight. Specific dosing information, including maximum daily doses, is provided in the official documentation. All calculations should be confirmed by a healthcare professional.

Q: Does Wilprafen solutab affect the ability to drive or use machinery?

A: Official information indicates that Wilprafen solutab generally does not have a negative effect on a person's ability to drive or operate machinery. However, official warnings note that some side effects, such as dizziness, may occur rarely, which could affect activities requiring concentration.

Q: What are the contraindications for Wilprafen solutab?

A: The official product information lists specific conditions that prevent use of the medicine, known as contraindications. These include severe liver function impairment and hypersensitivity (allergy) to josamycin or other medicines in the macrolide class. The complete list of contraindications is found in the prescribing information.

Q: Can Wilprafen solutab be crushed or chewed?

A: Wilprafen solutab is specifically designed to be dissolved in water before consumption. Product instructions state that the tablet should not be crushed or chewed directly. Following the recommended dissolution process helps ensure proper administration as intended by the product's design.

Q: Can I stop taking Wilprafen solutab when I feel better?

A: Regulatory information emphasizes the importance of completing the full prescribed course of treatment, even if symptoms begin to improve quickly. This measure is intended to help ensure the infection is completely treated and to support efforts in preventing the development of antibiotic resistance.

Storage Requirements

Official labeling requires Wilprafen Solutab (Josamycin dispersible tablets) to be stored in its original container and kept out of the sight and reach of children.

To preserve the product's stability, the tablets must be protected from moisture, heat, and direct sunlight, generally by storing them at a controlled room temperature, typically below 25 C.

Stability and Disposal

Due to stability concerns, any liquid suspension prepared by dissolving the tablet in water must be used immediately and any remainder must be discarded.

Unused or expired Wilprafen Solutab must not be flushed down a toilet or poured into a drain. The product should be disposed of via an authorized drug take-back program. If a take-back option is unavailable, the product may be mixed with an unappealing substance, placed in a sealed bag, and disposed of in the household trash, with all personal information scratched off the packaging.